Mangala Rao
Walter Reed Army Institute of Research
Lipid AAntigenMolecular biologyVirologyAntibodyMHC class ILiposomeChemistryEpitopeImmunologyVaccinationVirusAdjuvantHIV vaccineVaccine efficacyImmunizationImmunogenicityMonophosphoryl Lipid AHuman immunodeficiency virus (HIV)Monoclonal antibodyBiochemistryMedicineBiologyImmune systemCell biology
137Publications
35H-index
5,798Citations
Publications 124
Newest
#2Mangala Rao (WRAIR: Walter Reed Army Institute of Research)H-Index: 35
view all 12 authors...
A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum ant...
Source
#1M. Gordon Joyce (WRAIR: Walter Reed Army Institute of Research)H-Index: 5
#2Wei-Hung Chen (WRAIR: Walter Reed Army Institute of Research)H-Index: 3
Last. Elaine B. Morrison (WRAIR: Walter Reed Army Institute of Research)H-Index: 2
view all 60 authors...
The need for SARS-CoV-2 next-generation vaccines has been highlighted by the rise of variants of concern (VoC) and the long-term threat of emerging coronaviruses. Here, we designed and characterized four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion SARS-CoV-2 Spike (S), S1 and RBD. These immunogens induced robust S-binding, ACE2-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A Spike-...
Source
#2Giacomo GoriniH-Index: 6
Last. Genoveffa FranchiniH-Index: 91
view all 58 authors...
Summary The efficacy of ALVAC-based HIV and SIV vaccines in humans and macaques correlates with antibodies to envelope variable region 2 (V2). We show here that vaccine-induced antibodies to SIV variable region 1 (V1) inhibit anti-V2 antibody mediated cytotoxicity and reverse their ability to block V2 peptide interaction with the α4β7 integrin. SIV vaccines engineered to delete V1 and favor an α-helix, rather than a β-sheet V2 conformation, induced V2-specific ADCC correlating with decreased ris...
2 CitationsSource
#2Margherita RosatiH-Index: 30
Last. Barbara K. FelberH-Index: 69
view all 16 authors...
The RV144 vaccine trial revealed a correlation between reduced risk of HIV infection and the level of non-neutralizing antibody (Ab) responses targeting specific epitopes in the second variable domain (V2) of the HIV gp120 envelope (Env) protein, suggesting this region as a target for vaccine development. To favor induction of V2-specific Abs, we developed a vaccine regimen that included priming with DNA expressing an HIV V1V2 trimeric scaffold immunogen followed by booster immunizations with a ...
1 CitationsSource
#1Jiae Kim (WRAIR: Walter Reed Army Institute of Research)H-Index: 3
#1Jiae Kim (Henry M. Jackson Foundation for the Advancement of Military Medicine)H-Index: 6
Last. Mangala Rao (WRAIR: Walter Reed Army Institute of Research)H-Index: 35
view all 3 authors...
To prevent the spread of HIV-1, a vaccine should elicit antibodies that block viral entry for all cell types. Recently, we have developed a virus capture assay to quantitatively examine early time points of infection. Here we present data on the ability of bNAbs to inhibit capture (1 h) or replication (48 h) of purified primary acute or chronic HIV or infectious molecular clones (IMCs) in human peripheral blood mononuclear cells (PBMCs) as quantified by qRT-PCR. Although bNAbs significantly inhi...
Source
#1Agricola Joachim (MUHAS: Muhimbili University of Health and Allied Sciences)H-Index: 7
#2Frank Msafiri (MUHAS: Muhimbili University of Health and Allied Sciences)
Last. Gunnel Biberfeld (KI: Karolinska Institutet)H-Index: 63
view all 15 authors...
We evaluated antibody responses to the human immunodeficiency virus (HIV) envelope variable regions 1 and 2 (V1V2) in 29 vaccinees who had received three HIV-1 DNA immunizations and two HIV-modified vaccinia virus Ankara (MVA) boosts in the phase I/II HIVIS03 vaccine trial. Twenty vaccinees received a third HIV-MVA boost after three years in the HIVIS06 trial. IgG and IgG antibody subclasses to gp70V1V2 proteins of HIV-1 A244, CN54, Consensus C, and Case A2 were analysed using an enzyme-linked i...
1 CitationsSource
#1Mangala Rao (WRAIR: Walter Reed Army Institute of Research)H-Index: 35
#2Kristina K. Peachman (WRAIR: Walter Reed Army Institute of Research)H-Index: 20
Last. Carl R. Alving (WRAIR: Walter Reed Army Institute of Research)H-Index: 70
view all 3 authors...
Development of liposome-based formulations as vaccine adjuvants has been intimately associated with, and dependent on, and informed by, a fundamental understanding of biochemical and biophysical properties of liposomes themselves. The Walter Reed Army Institute of Research (WRAIR) has a fifty-year history of experience of basic research on liposomes; and development of liposomes as drug carriers; and development of liposomes as adjuvant formulations for vaccines. Uptake of liposomes by phagocyti...
1 CitationsSource
#1Frank Msafiri (MUHAS: Muhimbili University of Health and Allied Sciences)H-Index: 1
#2Agricola Joachim (MUHAS: Muhimbili University of Health and Allied Sciences)H-Index: 7
Last. Charlotta Nilsson (KI: Karolinska Institutet)H-Index: 18
view all 23 authors...
Antibody responses that correlated with reduced risk of HIV acquisition in the RV144 efficacy trial were assessed in healthy African volunteers who had been primed three times with HIV-DNA (subtype A, B, C) and then randomized into two groups; group 1 was boosted twice with HIV-MVA (CRF01_AE) and group 2 with the same HIV-MVA coadministered with subtype C envelope (Env) protein (CN54rgp140/GLA-AF). The fine specificity of plasma Env-specific antibody responses was mapped after the final vaccinat...
3 CitationsSource
#2Giacomo GoriniH-Index: 6
Last. Manuel Becerra-Flores (NYU: New York University)H-Index: 2
view all 58 authors...
The efficacy of ALVAC-based HIV and SIV vaccines in humans and macaques correlates with antibodies to envelope variable region 2 (V2). We show here that vaccine-induced antibodies to SIV variable region 1 (V1) inhibit anti-V2 antibody mediated cytotoxicity and reverse their ability to block V2 peptide interaction with the α4β7 integrin receptor. SIV vaccines engineered to delete V1 and favor an a-helix, rather than a β-sheet V2 conformation, enhanced V2-specific ADCC correlating with decreased r...
Source
#1Lindsay Wieczorek (Henry M. Jackson Foundation for the Advancement of Military Medicine)H-Index: 12
#2Kristina K. Peachman (WRAIR: Walter Reed Army Institute of Research)H-Index: 20
Last. Venigalla B. Rao (CUA: The Catholic University of America)H-Index: 43
view all 7 authors...
Abstract The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by several neutralizing antibodies (NAbs) and is of interest for vaccine design. In this study, we identified novel MPER peptide mimotopes and evaluated their reactivity with HIV + plasma antibodies to characterize the diversity of the immune responses to MPER during natural infection. We utilized phage display technology to generate novel mimotopes that fit antigen-binding sites of MPER NAbs 4E10, 2F5 and Z13. Plasm...
Source